These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38833966)

  • 1. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
    Thomas QD; Quantin X; Lemercier P; Chouaid C; Schneider S; Filleron T; Remon-Masip J; Perol M; Debieuvre D; Audigier-Valette C; Justeau G; Loeb A; Hiret S; Clement-Duchene C; Dansin E; Stancu A; Pichon E; Bosquet L; Girard N; Du Rusquec P
    ESMO Open; 2024 Jun; 9(6):103473. PubMed ID: 38833966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
    Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
    Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
    Bischoff P; Reck M; Overbeck T; Christopoulos P; Rittmeyer A; Lüders H; Kollmeier J; Kulhavy J; Kemper M; Reinmuth N; Röper J; Janning M; Sommer L; Aguinarte L; Koch M; Wiesweg M; Wesseler C; Waller CF; Kauffmann-Guerrero D; Stenzinger A; Stephan-Falkenau S; Trautmann M; Lassmann S; Tiemann M; Klauschen F; Sebastian M; Griesinger F; Wolf J; Loges S; Frost N;
    J Thorac Oncol; 2024 May; 19(5):803-817. PubMed ID: 38096950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
    Shire NJ; Klein AB; Golozar A; Collins JM; Fraeman KH; Nordstrom BL; McEwen R; Hembrough T; Rizvi NA
    PLoS One; 2020; 15(9):e0238358. PubMed ID: 32881920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and outcomes in KRAS
    Barghout SH; Zhan LJ; Raptis S; Al-Agha F; Esfahanian N; Popovacki A; Kasymjanova G; Proulx-Rocray F; Chan SWS; Richardson M; Brown MC; Patel D; Dean ML; Navani V; Moore E; Carvery L; Yan E; Goldshtein D; Cleary-Gosine J; Gibson AJ; Hubley L; Balaratnam K; Ngo T; Gill A; Black M; Sacher A; Bradbury PA; Shepherd FA; Leighl N; Cheema P; Kuruvilla S; Agulnik J; Banerji S; Juergens R; Blais N; Cheung W; Wheatley-Price P; Liu G; Snow S
    Lung Cancer; 2024 Aug; 194():107898. PubMed ID: 39074423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).
    Wu JJ; Lee PH; Zheng ZR; Huang YH; Tseng JS; Hsu KH; Yang TY; Yu SL; Chen KC; Chang GC
    Medicine (Baltimore); 2022 Jun; 101(24):e29381. PubMed ID: 35713442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
    Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
    Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
    Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
    Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Strickler JH; Yoshino T; Stevinson K; Eichinger CS; Giannopoulou C; Rehn M; Modest DP
    Oncologist; 2023 Nov; 28(11):e981-e994. PubMed ID: 37432264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Gibert J; Clavé S; Hardy-Werbin M; Taus Á; Rocha P; Longarón R; Piquer G; Chaib I; Carcereny E; Morán T; Salido M; Dalmases A; Bellosillo B; Arriola E
    Lung Cancer; 2020 Feb; 140():42-45. PubMed ID: 31862576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
    Justeau G; Huchot E; Simonneau Y; Roa M; Le Treut J; Le Garff G; Bylicki O; Schott R; Bravard AS; Tiercin M; Lamy R; De Chabot G; Marty A; Moreau D; Locher C; Bernier C; Chouaid C; Descourt R
    Lung Cancer; 2022 Dec; 174():45-49. PubMed ID: 36323057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.
    Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z
    Clin Transl Oncol; 2024 Oct; 26(10):2479-2487. PubMed ID: 38625494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
    Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
    BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
    Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
    Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
    Mazzaschi G; Perrone F; Minari R; Verzè M; Azzoni C; Bottarelli L; Pluchino M; Armillotta MP; Ubaldi A; Altimari A; Gruppioni E; Sperandi F; Andrini E; Guaitoli G; Bettelli S; Longo L; Bertolini F; Barbieri F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Gnetti L; Tiseo M;
    Clin Lung Cancer; 2022 Nov; 23(7):e478-e488. PubMed ID: 36002369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.
    Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A
    Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.
    Gray JE; Hsu H; Younan D; Suri G; Chia V; Spira A; Johnson M
    Lung Cancer; 2023 Jul; 181():107260. PubMed ID: 37285629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study.
    Frost MG; Jensen KJ; Gotfredsen DR; Sørensen AMS; Ankarfeldt MZ; Louie KS; Sroczynski N; Jakobsen E; Andersen JL; Jimenez-Solem E; Petersen TS
    Lung Cancer; 2023 Apr; 178():172-182. PubMed ID: 36868178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.